Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 43

Results For "generic"

711 News Found

U.S. District Court rules in favor of Merck in Sitagliptin Phosphate patent lawsuit
News | September 23, 2022

U.S. District Court rules in favor of Merck in Sitagliptin Phosphate patent lawsuit

Sitagliptin is an active ingredient in JANUVIA, JANUMET and JANUMET XR


Shilpa Medicare receives tentative approval for Tenofovir Alafenamide Tablets
Drug Approval | September 22, 2022

Shilpa Medicare receives tentative approval for Tenofovir Alafenamide Tablets

The ANDA was filed as 'First to File' submission on NCE-1 date.


Affordable Sitagliptin combinations for diabetics to be sold at Janaushadhi Kendras
Healthcare | September 19, 2022

Affordable Sitagliptin combinations for diabetics to be sold at Janaushadhi Kendras

Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus


Zydus receives final approval from USFDA for Cariprazine Capsules
Drug Approval | September 15, 2022

Zydus receives final approval from USFDA for Cariprazine Capsules

Cariprazine is an atypical antipsychotic indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder


Dr. Reddy's Laboratories launches Lenalidomide Capsules in the U.S.
News | September 09, 2022

Dr. Reddy's Laboratories launches Lenalidomide Capsules in the U.S.

Celgene agreed to provide Dr. Reddy's with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S.


Cipla receives US FDA approval for Revlimid (Lenalidomide) capsules
Drug Approval | September 08, 2022

Cipla receives US FDA approval for Revlimid (Lenalidomide) capsules

Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings


Lupin and DKSH sign licensing and supply agreement to market five biosimilar candidates in the Philippines
News | September 07, 2022

Lupin and DKSH sign licensing and supply agreement to market five biosimilar candidates in the Philippines

Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.


Hikma launches seasonal allergic rhinitis nasal spray RYALTRIS in the US
News | August 31, 2022

Hikma launches seasonal allergic rhinitis nasal spray RYALTRIS in the US

This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US


Lupin receives tentative approval from USFDA for Dasatinib Tablets
Drug Approval | August 29, 2022

Lupin receives tentative approval from USFDA for Dasatinib Tablets

Dasatinib Tablets (RLD Sprycel) had estimated annual sales of USD 1569 million in the U.S. (IQVIA MAT June 2022).